The androgen receptor (AR) is the primary transcription factor driving prostate tumorigenesis and disease progression, making it a central therapeutic target throughout most stages of prostate cancer, including castration-resistant prostate cancer (CRPC). Here, AR is linked to prostate carcinoma.